DISCUSSION
paresthesia, neuropathic pain, pain
PARESTHESIA
The results of this study demonstrate that SCS screening trials do not provide superior patient outcomes in the long-term when compared with not doing a screening trial. These findings support the initial conclusions at the 6-month primary end point.Clinically important reductions in pain intensity and improvements in health-related quality of life were observed at 36-month follow-up for both groups, confirming the long-term effectiveness of SCS. Previous long-term follow-ups of RCTs have reported similar effects of SCS for patients with neuropathic pain.Although our study was not powered for a comparison between the 3 waveforms used in this study (paresthesia stimulation, high frequency at 10 kHz, and burst), we did not observe clinically relevant differences between these waveforms at 6 or at 36 months. Discussion considering a smaller MCID is presented in Parallel and crossover RCTs have previously reported no differences in effectiveness when comparing different paresthesia-free frequencies,